AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01495897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracking eye movement
Description: Device: studying Saccadic eye movements with a video eye tracker: The subjects are seated in darkness facing a screen located 60 cm before their eyes, their chin on a chin strap and their forehead placed against a frontal support. Eye position is sampled at 500 Hz with a video-based monocular eye tracker (SMI, Germany). Each recording session start with a calibration test in which the subjects looked at nine consecutive targets covering the entire visual field, as used during the oculomotor paradigms: four experimental conditions: a visually guided saccade task, a pre-test, a backward adaptation task, and a post-test. The pre-test and post-test (40 trials each) are performed before and immediately after the backward adaptation task, in the same conditions, except that the target was extinguished when the velocity threshold (150°/s for 10 ms) is reached, instead of jumping to a new location.
Study NCT01495897 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tracking eye movement
Description: Device: studying Saccadic eye movements with a video eye tracker: The subjects are seated in darkness facing a screen located 60 cm before their eyes, their chin on a chin strap and their forehead placed against a frontal support. Eye position is sampled at 500 Hz with a video-based monocular eye tracker (SMI, Germany). Each recording session start with a calibration test in which the subjects looked at nine consecutive targets covering the entire visual field, as used during the oculomotor paradigms: four experimental conditions: a visually guided saccade task, a pre-test, a backward adaptation task, and a post-test. The pre-test and post-test (40 trials each) are performed before and immediately after the backward adaptation task, in the same conditions, except that the target was extinguished when the velocity threshold (150°/s for 10 ms) is reached, instead of jumping to a new location.
Study NCT01628874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA
Description: In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
Study NCT01495897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracking eye movement under deep brain stimulation
Description: Device: studying Saccadic eye movements with a video eye tracker. If the patient has deep brain stimulation, recording will be made in the morning, before the usual morning start of the deep brain stimulation.
Study NCT01869894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: metallic biliary stent insertion (double bare - S&G Biotech.)
Description: The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
Study NCT01869894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: metallic biliary stent insertion (single bare - S&G Biotech.)
Description: The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
Study NCT01869894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: metallic biliary stent insertion (single bare - Taewoong Medical.)
Description: The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
Study NCT05222347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Olive Leaf Tea
Description: Olive-leaf tea (OLT) is widely used in the traditional medicine in the Mediterranean region. Due to the high concentration of phenolic compounds, of which most abundant is oleuropein, interest in olive leaf has increased recently \[22, 23\]. The components of the olive leaves are known for their immune-modulatory, anti-inflammatory, antioxidant, hypoglycemic, antihypertensive, antimicrobial, and anti-atherosclerotic effects \[24, 25\]. Although its antiviral mechanism of action is not fully known, many studies have been conducted on the antiviral effects of olive leaf extract .
Study NCT01947374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Matrix encapsulated chondrocyte implantation
Description: Each implant contains 6,000,000 autologous chondrocytes.
Study NCT01947374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture awl
Description: Is an awl that allow perforation of the subchondral bone.
Study NCT02485366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rejuvesol
Description: Blood transfused during surgery will be treated with Rejuvesol.
Study NCT02485366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac surgery
Description: The study interventions will take place during a routine admission for pediatric open heart surgery. The anesthetic technique for subjects undergoing cardiac surgery is standard care and the research study interventions will not change these practices in any way.
Study NCT04150640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nal-IRI
Description: chemotherapy drug
Study NCT01628874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.
Study NCT01628874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.
Study NCT01579617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BUtiful.
Description: 8 website sessions include themes that teach: gender empowerment, assertive communication skills, goal setting, pregnancy and STI/HIV risk, safer sex behaviors, proper condom use, positive attitudes and norms towards consistent condom use, contraception, partner involvement in safer sex, and responsibility for their own health.
Study NCT01579617 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DIVAS.
Description: Attention control arm: 8 website sessions that include topics on: healthy eating, choosing nutritional snacks, sugar and salt intake, physical activity, stress management, foods for beauty.
Study NCT00795418 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT00795418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAD106
Study NCT01663675 — intervention group
Intervention type: GENETIC
Intervention: karyotype
Study NCT04132284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-Based Parenting Intervention
Description: The intervention will consist of 8-10 individual parent sessions, to be completed within one week after the teen completes the IOP program. Sessions will be 1 hour in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 10. Sessions will follow the standard agenda used for DBT skills training: 1) mindfulness practice, 2) homework review, 3) teaching of a new skill; 4) practice of the new skill; and 5) assignment of new homework (Linehan, 1993). The intervention will utilize the Middle Path module of the DBT Skills Manual for Adolescents (Rathus \& Miller, 2015), which was created by the developers of DBT for adolescents and includes both instructions for therapists and handouts for clients.
Study NCT04132284 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: No parenting intervention provided beyond standard practices in DBT IOP program.
Study NCT02433093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basimglurant
Description: Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.
Study NCT04150640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy drug
Study NCT04150640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: chemotherapy drug
Study NCT04150640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: immunotherapy
Study NCT04150640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: immunotherapy
Study NCT04150640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: immunotherapy
Study NCT00968916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombrabulin (AVE8062)
Description: Pharmaceutical form: injection solution~Route of administration: intravenous infusion
Study NCT02336308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Study NCT02336308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Normal Saline
Study NCT03074162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: twice daily
Study NCT03074162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac & Capsaicin
Description: twice daily
Study NCT03074162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium Topical Gel
Description: twice daily
Study NCT01513941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.
Study NCT01513941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.
Study NCT01513941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-Interferon-alfa-2a
Description: Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.
Study NCT02847416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreatheMAX breathing device
Study NCT03350191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR425899
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study NCT03350191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study NCT03350191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study NCT02308241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)
Study NCT00231582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: epirubicin
Study NCT00231582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-dose and autologous stem cell transplantation
Description: high-dose and autologous stem cell transplantation
Study NCT00231582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel
Study NCT00231582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: etoposide
Study NCT00231582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: ifosfamide
Study NCT00231582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin
Study NCT02435433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02435433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramucirumab
Description: Administered IV
Study NCT04539145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chocolate PTA Balloon
Description: Chocolate PTA Balloon
Study NCT02435433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT00964054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Public Health Dose of Exercise (PHD)
Description: 17.5 kcal per kilogram per week
Study NCT00964054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Exercise (LD)
Description: 7.0 kcal per kilogram per week
Study NCT01219140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2 POMx Capsules
Description: 2 POMx Capsules daily
Study NCT01219140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 2 placebo Capsules
Description: 2 placebo Capsules daily
Study NCT03973151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: HL-085 is one MEK inhibitor.
Study NCT03594617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children - for Caregiver
Description: Interaction Competencies with Children - for Caregiver (ICC-C) aims to reduce maltreatment and to improve care quality in institutional care facilities. Following the idea of a train-the-trainer approach, ICC-C is designed to be delivered by trained local facilitators. ICC-C is based on attachment, behavioral and social learning theories.~The key principles are its feasibility in low-resource contexts, participatory approach, and practical orientation. ICC-C includes sessions on (a) caregiver-child interaction, (b) maltreatment prevention, (c) effective non-violent caregiving strategies, and (d) identifying and supporting burdened children.
Study NCT03530241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Presence of bile duct stones
Description: MRCP verified gall stones in the bile ducts
Study NCT03530241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Non-presence of bile duct stones
Description: MRCP without bile duct stones
Study NCT02946255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Welcome Basket (WB)
Description: Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions.
Study NCT02946255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Welcome Basket Brief (WBbr)
Description: The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
Study NCT03973489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine Hydrochloride Tablets
Description: Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits. Participants will receive the following doses of methamphetamine hydrochloride in accordance with their weight: if weight is between 50-60 kg, 15 mg dose of methamphetamine hydrochloride will be administered. Similarly, for 60-80 kg, 20 mg dose; 80-100 kg, 25 mg dose; and 100+ kg, 30 mg dose.
Study NCT04539145 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: conventional balloon angioplasty
Description: conventional bal-loon angioplasty
Study NCT02872571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular Islet Autograft
Description: Intramuscular Islet Autograft After Extensive Pancreatectomy
Study NCT01900639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: change time of intake of aspirin
Study NCT01900639 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: change time of intake of aspirin
Study NCT00156702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback and Motivational Interviewing
Study NCT00156702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Prevention Video
Study NCT03348384 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]
Description: Radiolabel
Study NCT03348384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOP-1A
Description: Tracer
Study NCT03469388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse wave analyses; central blood presaure parameters
Description: Pulse wave analyses; central blood presaure parameters
Study NCT03010761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: antidepressant use for the betel-quid abstinence
Study NCT03010761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moclobemide
Description: antidepressant use for the betel-quid abstinence
Study NCT03010761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Cap
Description: Placebo - Cap
Study NCT01165580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir [Valcyte]
Description: oral dose, Days 1 and 2
Study NCT03504670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Amniotomy
Description: This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed prior to the cervix being dilated 4cm.
Study NCT03504670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Late Amniotomy
Description: This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed once the cervix is at least 4cm dilated.
Study NCT01863810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW21052
Description: 1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.
Study NCT01863810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica
Description: 1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.
Study NCT01863810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyrica (low dose)
Description: 1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.
Study NCT01863810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica (low dose)
Description: 1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.
Study NCT01863810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of KW21052
Description: Oral,once a day, for 8 weeks
Study NCT01863810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Lyrica
Description: Oral, twice a day, for 8 weeks.